Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study

Universitaire Ziekenhuizen KU Leuven2,000 enrolled

Overview

This project will provide novel data using a large cohort of more than 3000 transplanted patients. Risk and protective factors for SARS-CoV-2 infection and COVID-19 disease severity will be identified. The proportion of patients who develop antibodies after infection will be revealed. In this way the presence of these antibodies can be evaluated as a test for prior infection. Our study additionally will demonstrate how long these antibodies remain present and whether they are protective against a new infection.

Study Type

OBSERVATIONAL

Enrollment

2,000

Conditions

Covid19 SARS-CoV Infection Transplantation Infection

Interventions

SARS-CoV-2 IgGDIAGNOSTIC_TEST

Collection of clinical variables, assessment of IgG antibodies for SARS-CoV-2, plasma collection for translational immunology studies

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent Exclusion Criteria: * age under 18 years

Outcomes

Primary Outcomes

Prevalence and risk-factors for SARS-CoV-2 infection

Time frame: inclusion during 4 months

Prevalence and risk-factors for COVID-19

Time frame: inclusion during 4 months

Secondary Outcomes

Durability of IgG positivity

Durability of IgG positivity/immunity

Time frame: 12 months